BioPharmSignal logoBioPharmSignal

Biotech News

Neuronetics to Report First Quarter 2026 Financial and Operating Results and Host Conference Call

Neuronetics (STIM)NeuroneticsEarnings

MALVERN, Pa., April 21, 2026 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company”), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders and the maker of NeuroStar®

Open original release

Related news

STIMNeuronetics2026-05-05 11:50 EST

Neuronetics Reports First Quarter 2026 Financial and Operating Results

STIMNeuronetics2026-03-17 11:50 EST

Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

CVRXCVRx2026-04-27 20:30 EST

CVRx to Report First Quarter 2026 Financial and Operating Results and Host Conference Call on May 11, 2026

ICCMIceCure Medical2026-05-06 12:30 EST

IceCure Medical to Report First Quarter 2026 Financial and Operating Results on May 12, 2026

CVRXCVRx2026-05-11 20:05 EST

CVRx Reports First Quarter 2026 Financial and Operating Results

AORTArtivion2026-04-23 20:15 EST

Artivion Announces Release Date and Teleconference Call Details for First Quarter 2026 Financial Results

IARTIntegra LifeSciences2026-04-20 12:32 EST

Integra LifeSciences to Host First Quarter 2026 Financial Results Conference Call on May 5, 2026

DNLIDenali Therapeutics2026-07-27 20:01 EST

Denali Therapeutics to Report Second Quarter 2026 Financial Results and Business Highlights on August 6, 2026

PAVMPAVmed2026-05-14 12:00 EST

Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results

ICCMIceCure Medical2026-05-12 12:30 EST

IceCure Reports First Quarter 2026 Financial Results: ProSense® Sales Increase Substantially in the U.S. and North America

View all latest news

Neuronetics

Neuronetics is a medical device company focused on neurostimulation for depression and mental-health treatment. Its business is centered on procedure-based adoption of non-drug therapy.

Recent company news

STIMNeuronetics2026-06-02 20:30 EST

Neuronetics Appoints Robert Greene as Senior Vice President Sales

STIMNeuronetics2026-06-02 12:32 EST

Neuronetics Highlights Continued Advancements in TMS Research at CTMSS 2026

STIMNeuronetics2026-05-14 12:32 EST

Neuronetics and ANT Neuro Announce Strategic Collaboration to Integrate Neuronavigation with NeuroStar TMS Treatment

STIMNeuronetics2026-05-05 11:50 EST

Neuronetics Reports First Quarter 2026 Financial and Operating Results

STIMNeuronetics2026-04-29 20:30 EST

Neuronetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Stock data

Close
1.81 USD
Market cap
108.56M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States